UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of "Buy" by Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have earned an average rating of "Buy" from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $38.20.

A number of equities research analysts have recently commented on the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price objective for the company. HC Wainwright dropped their price objective on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Monday, March 10th.

Insiders Place Their Bets

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Institutional Trading of UroGen Pharma

Large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma in the fourth quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in UroGen Pharma during the 4th quarter worth approximately $67,000. GAMMA Investing LLC boosted its holdings in UroGen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after acquiring an additional 7,392 shares during the period. BNP Paribas Financial Markets grew its position in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of UroGen Pharma during the fourth quarter valued at approximately $101,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Trading Up 1.4 %

Shares of NASDAQ URGN traded up $0.15 during midday trading on Thursday, reaching $10.75. 157,862 shares of the stock were exchanged, compared to its average volume of 508,701. The stock has a 50 day moving average price of $10.53 and a 200-day moving average price of $11.24. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market capitalization of $495.51 million, a P/E ratio of -3.41 and a beta of 0.80. UroGen Pharma has a 52-week low of $8.94 and a 52-week high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to analysts' expectations of $25.25 million. Equities research analysts expect that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.